Share of Clicks for top 10 US Pharma & Biotech Infectious Diseases brands
Here are the Top 10 competitors in the industry by Share of Clicks for the last month.
| Domain | Share of clicks |
|---|---|
| paxlovid.com | 34.48 |
| mavyret.com | 13.29 |
| uqora.com | 6.41 |
| mayoclinic.org | 3.17 |
| symtuzahcp.com | 3.14 |
| talk-prep.com | 2.98 |
| cabenuva.com | 2.96 |
| dndi.org | 2.85 |
| admired.com | 2.74 |
| epclusa.com | 2.61 |
| others | 25.37 |
- paxlovid.com - 34.48%
- mavyret.com - 13.29%
- uqora.com - 6.41%
- mayoclinic.org - 3.17%
- symtuzahcp.com - 3.14%
- talk-prep.com - 2.98%
- cabenuva.com - 2.96%
- dndi.org - 2.85%
- admired.com - 2.74%
- epclusa.com - 2.61%
- others - 25.37%
Copyright © Adthena. All rights reserved.
In the PPC landscape, paxlovid.com dominates with 34.48% click share, followed by others at 25.37%. Mavyret.com holds 13.29%, while uqora.com captures 6.41%.
Share of Spend for the top 10 US Pharma & Biotech Infectious Diseases brands
Curious about your market position? Here you can see the Top 10 competitors in the industry by Share of Spend for the last month.
| Date | mavyret.com | paxlovid.com | cabenuva.com | skyrizi.com | uqora.com | talk-prep.com | mayoclinic.org | symtuzahcp.com | dndi.org | epclusa.com |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/03/01 | 22.3% | 10.2% | 8.14% | 4.38% | 6.22% | 6.31% | 3.57% | 2.24% | 1.05% | 4.95% |
| 2026/03/02 | 21.01% | 6.49% | 0.25% | 4.53% | 12.87% | 5.11% | 0.65% | 3.85% | 3.4% | 2.63% |
| 2026/03/03 | 14.92% | 7.49% | 7.12% | 2.83% | 13.12% | 3.5% | 2.34% | 2.83% | 6.02% | 7.35% |
| 2026/03/04 | 10.13% | 13.62% | 5.09% | 3.01% | 13.68% | 4.23% | 5.72% | 4.2% | 3.44% | 1.97% |
| 2026/03/05 | 18.76% | 11.19% | 0.22% | 4.25% | 4.26% | 5.57% | 2.19% | 6.28% | 5.48% | 2.41% |
| 2026/03/06 | 21.81% | 11.98% | 11.4% | 2.11% | 5.35% | 4.22% | 1.77% | 3.99% | 5.01% | 6.15% |
| 2026/03/07 | 24.63% | 8.24% | 2.48% | 3.23% | 3.75% | 6.12% | 0.54% | 8.81% | 4.98% | 2.68% |
| 2026/03/08 | 21.58% | 15.07% | 3.4% | 1.68% | 0% | 6.12% | 3.5% | 4.61% | 2.55% | 6.87% |
| 2026/03/09 | 14.97% | 20.54% | 10.26% | 1.66% | 0% | 3.34% | 8.29% | 0.86% | 2.3% | 5.69% |
| 2026/03/10 | 19.33% | 15.46% | 1.82% | 5.08% | 0% | 4.37% | 7.49% | 2.96% | 0.49% | 4.07% |
| 2026/03/11 | 16.43% | 18.88% | 7.97% | 4.87% | 3.56% | 4.25% | 0.25% | 2% | 5.04% | 3.43% |
| 2026/03/12 | 14.88% | 13.3% | 1.81% | 4.07% | 0% | 4.77% | 5.98% | 6.52% | 1.49% | 6.41% |
| 2026/03/13 | 16.29% | 31.83% | 3.13% | 2.81% | 0% | 4.91% | 0.3% | 1.99% | 6.17% | 4.42% |
| 2026/03/14 | 12.13% | 18.85% | 6.2% | 4.19% | 0% | 5.37% | 2.29% | 4.18% | 2.88% | 4.73% |
| 2026/03/15 | 13.6% | 13.47% | 8.91% | 2.57% | 0.05% | 4.26% | 3.02% | 6.55% | 3.83% | 2.69% |
| 2026/03/16 | 15.89% | 18.2% | 1.95% | 4.48% | 0.05% | 4.11% | 6.94% | 4.24% | 3.96% | 4.3% |
| 2026/03/17 | 13.34% | 6.54% | 8.61% | 3.67% | 0.23% | 3.71% | 3.38% | 4.31% | 5.72% | 6.32% |
| 2026/03/18 | 21.73% | 7.36% | 8.6% | 3.67% | 0% | 4% | 3.01% | 3.9% | 6.69% | 4.2% |
| 2026/03/19 | 18.46% | 12.52% | 11.97% | 4.27% | 0% | 5.19% | 6.24% | 2.2% | 5.18% | 1.29% |
| 2026/03/20 | 18.53% | 13.87% | 7.05% | 2.89% | 3.48% | 4.73% | 5.32% | 3.69% | 7.79% | 2.31% |
| 2026/03/21 | 14.43% | 19.66% | 12.21% | 2.41% | 0% | 4.42% | 6.37% | 4.79% | 2.37% | 2.6% |
| 2026/03/22 | 19.82% | 2.45% | 13.67% | 4.6% | 2.19% | 6.22% | 4.38% | 5.13% | 3.81% | 2.78% |
| 2026/03/23 | 17.32% | 9.72% | 12% | 2.6% | 1.98% | 3.92% | 0.99% | 6.14% | 2.75% | 2.65% |
| 2026/03/24 | 12.5% | 14.91% | 12.01% | 3.64% | 10.24% | 8.01% | 3.28% | 0.51% | 4.92% | 1.13% |
| 2026/03/25 | 9.7% | 10.03% | 6.36% | 3.16% | 8.51% | 5.68% | 4.72% | 7.02% | 0.59% | 2.49% |
| 2026/03/26 | 9.38% | 20.01% | 8.3% | 2.29% | 6.74% | 4.28% | 3.56% | 3.64% | 0.78% | 1.9% |
| 2026/03/27 | 17.47% | 4.51% | 8.39% | 2.8% | 3.67% | 6.68% | 0.07% | 8.42% | 0.69% | 5.34% |
| 2026/03/28 | 12.82% | 25.02% | 4.65% | 1.63% | 0% | 5.48% | 2.12% | 5.96% | 2.83% | 3.88% |
| 2026/03/29 | 15.93% | 17.48% | 9.39% | 2.7% | 5.9% | 6.79% | 1.1% | 4.31% | 0.39% | 1.29% |
| 2026/03/30 | 10.62% | 11.02% | 10.7% | 4.62% | 9.41% | 5.4% | 7.88% | 1.48% | 0.1% | 1.67% |
| 2026/03/31 | 22.97% | 11.18% | 7.72% | 5.96% | 5.05% | 3.6% | 2.4% | 2.08% | 1.74% | 1.7% |
- mavyret.com
- paxlovid.com
- cabenuva.com
- skyrizi.com
- uqora.com
- talk-prep.com
- mayoclinic.org
- symtuzahcp.com
- dndi.org
- epclusa.com
Copyright © Adthena. All rights reserved.
Mavyret.com led March with fluctuating ad spend, peaking at 24.63% on March 7. Paxlovid.com surged mid-month, reaching 31.83% on March 13. Cabenuva.com maintained steady growth, while Skyrizi.com and Uqora.com showed moderate fluctuations. Talk-prep.com and Mayoclinic.org had consistent, lower spend. Symtuzahcp.com and Dndi.org experienced varied trends, with Epclusa.com ending March with a slight decline.
Competitor Count for US Pharma & Biotech Infectious Diseases
Ever wondered how many competitors you’re up against in your industry? Well look no further, here we can see the number of advertisers bidding over the last month.
| Date | Competitor Count |
|---|---|
| 2026/03/01 | 71 |
| 2026/03/02 | 76 |
| 2026/03/03 | 72 |
| 2026/03/04 | 73 |
| 2026/03/05 | 75 |
| 2026/03/06 | 72 |
| 2026/03/07 | 71 |
| 2026/03/08 | 68 |
| 2026/03/09 | 68 |
| 2026/03/10 | 66 |
| 2026/03/11 | 69 |
| 2026/03/12 | 66 |
| 2026/03/13 | 65 |
| 2026/03/14 | 70 |
| 2026/03/15 | 68 |
| 2026/03/16 | 72 |
| 2026/03/17 | 72 |
| 2026/03/18 | 64 |
| 2026/03/19 | 63 |
| 2026/03/20 | 71 |
| 2026/03/21 | 68 |
| 2026/03/22 | 61 |
| 2026/03/23 | 62 |
| 2026/03/24 | 58 |
| 2026/03/25 | 61 |
| 2026/03/26 | 59 |
| 2026/03/27 | 59 |
| 2026/03/28 | 58 |
| 2026/03/29 | 59 |
| 2026/03/30 | 60 |
| 2026/03/31 | 63 |
Copyright © Adthena. All rights reserved.
March began with 71 advertisers, peaking at 76 on March 2. A gradual decline followed, ending the month at 63.
